Physician profile
Rebecca L Smith
NPI 1366412033
$2,281,134.82
in general payments reported to CMS, 2019-2025
44 companies · $324K in 2025
The $324K reported for 2025 was more than what 99% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $266K · 2020: $219K · 2021: $334K · 2022: $422K · 2023: $475K · 2024: $241K · 2025: $324K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $681K · Consulting Fee: $214K · Travel and Lodging: $98K · Food and Beverage: $30K · Honoraria: $17K · Education: $419.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $681,014.18 |
| Consulting Fee | $214,302.32 |
| Travel and Lodging | $97,764.36 |
| Food and Beverage | $29,567.98 |
| Honoraria | $16,800.00 |
| Education | $419.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $492,489.18 | 2019-2025 | Otezla, Otezla |
| Genzyme Corporation | $259,206.77 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $244,063.53 | 2019-2025 | Dupixent |
| Arcutis Biotherapeutics, INC. | $219,347.22 | 2023-2025 | Zoryve |
| Lilly USA, LLC | $217,798.03 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Pfizer INC. | $184,460.73 | 2019-2025 | |
| Abbvie INC. | $129,808.67 | 2019-2025 | Rinvoq, Skyrizi |
| Celgene Corporation | $120,344.54 | 2019 | |
| Vyne Pharmaceuticals INC. | $94,167.57 | 2020-2021 | |
| Incyte Corporation | $92,583.43 | 2021-2025 | Opzelura |
| Galderma Laboratories, L.P. | $46,280.92 | 2019-2025 | Aklief, Epsolay, Oracea |
| Organon LLC | $30,538.02 | 2025 | Vtama, Nexplanon |
| Epi Health, LLC | $28,319.04 | 2019-2022 | |
| Janssen Scientific Affairs, LLC | $26,966.27 | 2019-2025 | Tremfya, Stelara |
| Kowa Pharmaceuticals America, INC. | $19,032.90 | 2025 | Zoryve |
Show all 43 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rebecca Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.